Insamo transforms drug discovery for challenging diseases using an automated platform for designing, synthesizing, and testing compounds. This process leverages trillions of proprietary experimental data points across vast chemical space. The company applies scalable machine learning to accelerate and set a new standard for drug design iteration cycles.
Funding
$21.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many biologic drugs require administration via injection, which can be inconvenient and uncomfortable for patients. Identifying orally available alternatives that maintain the binding affinity of biologics is a significant challenge in drug discovery.
Solution
Insamo is developing a biotechnology platform that leverages automated molecular biology and parallel synthetic chemistry to discover membrane-permeable, orally available cyclic peptides. These peptides are designed to mimic the binding affinity of antibodies, potentially replacing injected biologics with oral formulations. The platform facilitates rapid identification of preclinical candidates through high-throughput design, synthesis, and testing, generating vast amounts of experimental data. This data is then used to train machine learning models for improved drug design.
Target Audience
The primary target audience includes pharmaceutical companies seeking to develop orally available alternatives to injectable biologic drugs, as well as patients who would benefit from more convenient drug administration.
Features
- Automated design, synthesis, and testing of cyclic peptides at scale
- Generation of trillions of proprietary experimental data points
- Scalable machine learning models for drug design optimization
- Identification of membrane-permeable, orally available cyclic peptides
- Cyclic peptides with antibody-like binding affinity